Zhengqiang Yuan

List of Publications by Year
in descending order

9	271	1684188 5	1474206 9
papers	citations	h-index	g-index

9	9	9	514
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The polysaccharides from Yiqi Yangyin complex attenuated mammary gland hyperplasia: Integrating underlying biological mechanisms and network pharmacology. Journal of Functional Foods, 2022, 88, 104878.	3.4	1
2	Sensitizing TRAIL response via differential modulation of anti- and pro-apoptotic factors by AZD5582 combined with ER nanosomal TRAIL in neuroblastoma. Acta Histochemica, 2022, 124, 151856.	1.8	3
3	EV-T synergizes with AZD5582 to overcome TRAIL resistance through concomitant suppression of cFLIP, MCL-1, and IAPs in hepatocarcinoma. Journal of Molecular Medicine, 2022, 100, 629-643.	3.9	6
4	Ginsenoside Rb1 protected PC12Âcells from AÎ²25-35-induced cytotoxicity via PPARÎ³ activation and cholesterol reduction. European Journal of Pharmacology, 2021, 893, 173835.	3.5	12
5	TRAILâ€Armed ER Nanosomes Induce Drastically Enhanced Apoptosis in Resistant Tumor in Combination with the Antagonist of IAPs (AZD5582). Advanced Healthcare Materials, 2021, 10, e2100030.	7.6	4
6	Extracellular Vesicle Delivery of TRAIL Eradicates Resistant Tumor Growth in Combination with CDK Inhibition by Dinaciclib. Cancers, 2020, 12, 1157.	3.7	30
7	TRAIL delivery by MSCâ€derived extracellular vesicles is an effective anticancer therapy. Journal of Extracellular Vesicles, 2017, 6, 1265291.	12.2	134
8	Cryopreservation of human mesenchymal stromal cells expressing TRAIL for human anti-cancer therapy. Cytotherapy, 2016, 18, 860-869.	0.7	30
9	Mesenchymal stromal cell delivery of full-length tumor necrosis factorâ€“related apoptosis-inducing ligand is superior to soluble type for cancer therapy. Cytotherapy, 2015, 17, 885-896.	0.7	51